16 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 8 Phase 2, 6 Phase 3, 4 Phase 1, 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 6 | Completed 2, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 4 | 4 | Completed 4 |
Follow Typhoid: new trials by email Literature Review of Typhoid trials Research Report on Typhoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ZyVac-TCV Bangladesh Study Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV - Typhoid Vaccination, Typhoid | Phase 3 | Not yet recruiting | International Centre for Diarrhoeal Disease Research, Bangladesh | 4000 | 2025-04-01 | 2025-02-07 |
| Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever Levofloxacin, ciprofloxacin - Typhoid, Fever | Phase 2 | Completed | Avicenna Medical College Lahore | 360 | 2025-02-07 | 2025-09-02 |
| Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM - Typhoid | Phase 2 | Completed | Kathleen Neuzil | 147 | 2024-08-17 | 2026-06-03 |
| Co-administration Study of OCV, TCV and MR Oral Cholera Vaccine (OCV), Typhoid Conjugate Vaccine (TCV), Measles and Rubella (MR) - Typhoid, Cholera | Phase 3 | Unknown | International Centre for Diarrhoeal Disease Research, Bangladesh | 2117 | 2023-10-14 | 2023-10-13 |
| Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) - Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 630 | 2022-07-01 | 2024-12-24 |
| Transcriptomic Responses for the Identification of Pathogens 5-gene transcription signature - Enteric Fever, Acute Febrile Illness | Recruiting | University of Sheffield | 2000 | 2022-05-02 | 2025-03-03 | |
| Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine - Typhoid | Phase 3 | Completed | International Vaccine Institute | 1800 | 2020-02-04 | 2021-08-27 |
| Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV® - Typhoid | Phase 3 | Unknown | International Vaccine Institute | 1800 | 2019-11-15 | 2020-04-22 |
| Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Vi-Typhoid Conjugate Vaccine (Vi-TCV), Inactivated Poliovirus Vaccine (IPV) - Typhoid | Phase 2 | Completed | University of Maryland, Baltimore | 251 | 2018-12-03 | 2025-05-30 |
| Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Vi-DT, FluQuadri™, 0.9% sodium chloride isotonic solution - Typhoid | Phase 2 | Completed | International Vaccine Institute | 285 | 2018-04-18 | 2021-08-27 |
| Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Vi-Typhoid Conjugate Vaccine (Vi-TCV), Meningococcal A Conjugate Vaccine (MCV-A) - Typhoid | Phase 3 | Active not recruiting | University of Maryland, Baltimore | 30000 | 2018-02-21 | 2026-09-17 |
| Effects of Aging on Primary and Secondary Vaccine Responses Fluzone® quadrivalent, Fluzone High Dose, Fluad - Influenza, Hepatitis A | Phase 1 | Completed | Stanford University | 54 | 2017-09-19 | 2024-12-16 |
| Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine Vi-DT, Typhim Vi®, VAXIGRIP® - Typhoid | Phase 1 | Completed | International Vaccine Institute | 144 | 2016-05-19 | 2020-04-28 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 552 | 2011-11-01 | 2014-03-11 |
| Understanding Typhoid Disease After Vaccination Vaccine placebo (excipients only), Ty21a, M10ZH09 vaccine - Typhoid Fever, Enteric Fever | Phase 2 | Completed | University of Oxford | 99 | 2011-10-07 | 2023-05-06 |
| Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3) - Typhoid | Phase 2 | Completed | Emergent BioSolutions | 187 | 2008-05-01 | 2024-04-09 |
| Studies of Immune Responses to Orally Administered Vaccines in Developing Country Placebo, Control, Zinc Sulphate - Cholera, Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 1016 | 2008-02-01 | 2011-07-12 |
| Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Typhoid Vi vaccine, Hepatitis A vaccine - Typhoid, Paratyphoid Fever | Phase 4 | Completed | International Vaccine Institute | 37673 | 2003-05-01 | 2008-08-26 |
| Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam Typhoid Vi vaccine, Hepatitis A (control) - Typhoid, Paratyphoid Fever | Phase 4 | Completed | International Vaccine Institute | 100742 | 2001-12-01 | 2008-03-13 |
| Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China Typhoid Vi vaccine, Meningococcal A (control) - Typhoid, Paratyphoid Fever | Phase 4 | Completed | International Vaccine Institute | 96468 | 2001-10-01 | 2008-03-13 |
Showing 20 of 21. Sign in to see all of them.
Typhoid Fever (21) · Paratyphoid Fever (5) · Cholera (2) · Fever (2) · Encephalitis, Japanese (1) · Hepatitis A (1) · Influenza, Human (1) · Measles (1) · Meningitis, Meningococcal (1) · Meningococcal Infections (1) · Rabies (1) · Rubella (1) · Salmonella Infections (1) · Yellow Fever (1)
Bacterial Infections (21) · Bacterial Infections and Mycoses (21) · Enterobacteriaceae Infections (21) · Gram-Negative Bacterial Infections (21) · Infections (21) · Salmonella Infections (20) · RNA Virus Infections (3) · Virus Diseases (3) · Body Temperature Changes (2) · Mononegavirales Infections (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Vibrio Infections (2) · Arbovirus Infections (1) · Brain Diseases (1)
Vi polysaccharide vaccine, typhoid (7) · Hepatitis A Vaccines (4) · Ty21a typhoid vaccine (2) · Albendazole (1) · Arsenic (1) · Carrier Proteins (1) · Cholera Vaccines (1) · Ciprofloxacin (1) · Diphtheria Toxoid (1) · Dosage Forms (1) · Fluzone High-Dose (1) · Japanese Encephalitis Vaccines (1) · Levofloxacin (1) · MenACWY-CRM vaccine (1) · Poliovirus Vaccine, Inactivated (1)
International Vaccine Institute (8) · International Centre for Diarrhoeal Disease Research, Bangladesh (4) · University of Maryland, Baltimore (2) · Avicenna Medical College Lahore (1) · Emergent BioSolutions (1) · Kathleen Neuzil (1) · Novartis (1) · Stanford University (1) · University of Oxford (1) · University of Sheffield (1)
Bangladesh (3) · Burkina Faso (2) · India (2) · Pakistan (2) · Philippines (2) · United States (2) · China (1) · Czechia (1) · Germany (1) · Malawi (1) · Nepal (1) · United Kingdom (1) · Vietnam (1)
Maria Rosario Capeding, MD (2) · Andrew J Pollard (1) · Canh G Do, MD (1) · Cornelia Dekker, MD (1) · Dong Baiqing, MD (1) · Farhana Khanam, MPhil, PhD (1) · Firdausi Qadri, PhD (1) · Ganesh Kumar Rai, MD (1) · Josefina C Carlos, MD (1) · Laurens Matthew, MD (1) · Matthew Laurens, MD (1) · Md Taufiqul Islam, MBBS, MPH (1) · Professor Aneela Zareen, MBBS FCPS (1) · Scott Boyd, MD, PhD (1) · Stephen Lockhart, DM (1)
PMID 19625715, PMID 20188175, PMID 24873986, PMID 25308927, PMID 27533046, PMID 29776750, PMID 30845320, PMID 30845330, PMID 31585725, PMID 33150320, PMID 34525285, PMID 34942090, PMID 35664443, PMID 35961356, PMID 38281499, PMID 40446606
R01AI130398 (1)